About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

Kessler Topaz Meltzer & Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information.

Dexcom shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.mo ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10 ...

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

If you need to track your glucose daily, you probably want a pain-free option. Besides pricking your finger, there are now wearable devices that are placed on your arm and connect to an app on your ...